DMAC
NASDAQ · Biotechnology
Diamedica Therapeutics Inc
$10.77
+0.77 (+7.70%)
Open$10.15
Previous Close$10.00
Day High$11.00
Day Low$10.15
52W High$11.00
52W Low$5.25
Volume—
Avg Volume258.4K
Market Cap516.61M
P/E Ratio—
EPS$-0.72
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
-61.4% upside
Current
$10.77
$10.77
Target
$4.16
$4.16
$2.49
$4.16 avg
$4.48
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 75.08M | 73.96M | 78.61M |
| Net Income | 7.50M | 6.55M | 6.83M |
| Profit Margin | 10.0% | 8.9% | 8.7% |
| EBITDA | 9.74M | 10.19M | 9.65M |
| Free Cash Flow | 6.22M | 6.24M | 10.05M |
| Rev Growth | +22.4% | +12.6% | +21.2% |
| Debt/Equity | 0.48 | 0.47 | 0.46 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.31 | +1.07% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $460.42 | +0.03% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $166.89 | -0.41% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $547.09 | +0.85% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $904.35 | +0.16% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $155.94 | -0.46% | 7.7 | 20.98B |